Clear proof of concept is the keyIf they can come up with clear efficacy results, the stock price will rise significantly. By how much? It is hard to tell with this market, but if the skepticism barrier is broken, then the pendulum could swing totally to the positive side. If that happen, this will mean access to a lot of money to drive this program aggressively.
Again, we are not talking about one molecule aiming at only one type of cancer. A clear proof of concept would open the door to a very wide array of possibilities, and one of the great thing is that it is a simple technology that can be quickly applied to all kinds of anti-cancer agents. The peptide is easy to make and they have it under GMP grade, approved drugs already exist, they don't need to make them, they just need to buy GMP grade API of these molecules. Then the only new process for each of them will be to link the anti-cancer agent to the peptide. Marsolais said in the last presentation that they can attach any drug to TH19P01, and I know that radioisotopes would be easy to attach too.
So we are not talking about very complex technology here, like CAR T-cell, or personalized stuff like that. What I am trying to explain is that the manufacturing side would be quick to develop for any new combination of TH19P01 + linker + cytotoxic agent. The three pieces can be manufactured seperatly under GMP and everything. Then, for every new project it would only be the final assembly of the three parts that would need to be validated. So it would be a very rapid process by normal pharmaceutical standards. So money would allow a lot of things that are not very complex.